The Centers for Disease Control and Prevention released its third set of nationally representative data on serum levels of polychlorinated dibenzodioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and non-ortho and coplanar polychlorinated biphenyls (PCBs) in the United States collected during the 2003-2004 sampling period as part of the National Health and Nutrition Examination Survey (NHANES). We utilize the serum PCDD/F data from the three NHANES sampling periods spanning 1999-2004 to assess whether there are discernable temporal trends in the United States, either for the overall population or by age. We also compare population serum data to biomonitoring equivalents (BEs) derived for PCDDs/Fs/PCBs; BEs are estimates of the concentration of PCDD/Fs/PCBs corresponding to existing exposure guidance values estimated by various governmental agencies. The serum PCDD/F data from 1999 to 2004 provide evidence that levels in the US population are declining, mirroring international trends, although the lower levels are principally observable in the 2003-2004 time period. Examining the trend by population age, from the 1999 to 2004, PCDD/F serum levels decreased by 56% for the 12-to 19-year-old group and by 38% for the 20-to 39-year olds. A slight nonsignificant decrease was observed for 40-to 59-year olds and a slight significant increase was found for 60 þ year olds. Interpretation of the data across time is complicated by certain aspects of the data unique to the various sampling time periods; thus, caution should be exercised when evaluating trend information. The population mean PCDD/F/ PCB TEQ is approximately equal to the BE based on the Agency for Toxic Substances and Disease Registry's Minimum Risk Level and is approximately 2-4 times lower than the remaining BEs, placing the population mean at the border between medium and low priority levels. However, certain segments of the population have levels at the medium/high priority level (e.g., the 95th percentiles for ages 60 years and older).
Introduction
The Centers for Disease Control and Prevention (CDC) recently released nationally representative data on serum levels of polychlorinated dibenzodioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and non-ortho and coplanar polychlorinated biphenyls (PCBs) These data have been used to estimate reference ranges for the US population (CDC, 2003 (CDC, , 2005 , including age-specific reference ranges . With data from three sampling periods now available, temporal trends in serum PCDD/F levels in the United States from 1999 to 2004 can be examined. This type of assessment can provide information on the efficacy of controls on emissions of these compounds, although a simple relationship between time because emission controls and declining environmental and human levels is unlikely given the long environmental and physiological half-lives of these compounds, natural sources of PCDDs/Fs, and issues related to evolving analytical methodologies with associated changes in method detection limits. A recent evaluation of international data on breast milk PCDD/F levels suggested a decline in levels from 1970s forward (LaKind, 2007) , although no nation-wide systematic sampling and analysis of breast milk has been carried out in the United States (LaKind et al., 2001) . Previous evaluations of ad hoc sampling data on PCDDs/Fs in serum and other human tissues have also suggested declining trends over the period from the 1970s through the year 2000 (Lorber, 2002; Hays and Aylward, 2003) . The data resulting from the nation-wide, systematic sampling program conducted through the NHANES program over the period from 1999 to 2004 provide an opportunity to examine serum concentrations of these compounds to assess whether these declining trends are apparent over the relatively short-time frame covered by this sampling program in the United States.
The 2003-2004 serum PCDD/F data can also be compared to a biomonitoring equivalent (BE), which is a concentration or range of concentrations of a chemical in a biological medium such as blood or urine consistent with existing health-based exposure guidelines (Hays et al., 2007) . BEs are screening tools for assessing whether chemicals have large, small, or no margin of safety compared to existing health-based exposure guidelines. In general, BEs are derived from chemical-specific human or animal pharmacokinetic data and points of departure such as no observed effect levels (NOELs), lowest observed effect levels (LOELs), or benchmark doses associated with the exposure guideline(s). Detailed guidelines for the derivation and communication of BEs are available LaKind et al., 2008) and BEs have been developed for PCDDs/Fs/dioxin-like PCBs (Aylward et al.) .
In this paper, we utilize the serum PCDD/F data from the three NHANES sampling periods spanning 1999-2004 to assess whether there are discernable temporal trends in the United States, either for the overall population or by age. For this part of the analysis, we focus on the 10 PCDD and 7 PCDF congeners with chlorine in the 2,3,7,8-positions. We then compare the population serum data to BEs derived for PCDDs/Fs. Because these BEs are based on exposure guidelines that include structurally related PCBs, we also examine the NHANES PCDD/F data in conjunction with the following PCBs for which there are NHANES data: three non-ortho-substituted PCBs (PCB 81, 126, and 169) and six mono-ortho-substituted PCBs (PCB 105, 118, 156, 157, 167, and 189) .
Methods
Throughout this paper, we use the World Health Organization (WHO) Toxic Equivalency (TEQ) method when giving concentrations of PCDD/Fs/PCBs, which assigns estimates of relative potency (Toxicity Equivalency Factors, or TEFs) to each compound compared to the most potent of the dioxinsF2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)F and sums the products of the concentration and TEF for each chemical (van den Berg et al., 2006) . The data are given in units of pg TEQ/g lipid, or parts per trillion. (Needham et al., 2007) .
Analysis of NHANES Serum Data
For individuals with missing data (data for only 16 or fewer congeners available), missing values were imputed using the following method. For each chemical, rank concentration data were used to arrive at a monotone transformation making the marginal distribution of transformed concentrations standard normal. Then for each subject, the available transformed values were averaged, and for each chemical with missing values, the inverse transform was used to arrive at a concentration for that chemical. To evaluate the impact of the imputation method on analysis, two additional analyses were performed, one in which missing values were set equal to zero, and another in which they were set equal to the maximum value observed for the congener in the sampling timeframe under consideration. These analyses yielded virtually identical concentration percentiles.
Development of BEs for PCDDs/Fs and Structurally Related PCBs
We briefly describe here the method used to develop BE values for the PCDDs/Fs and structurally related PCBs; detailed information is given in Aylward et al., 2008 . Several agencies have conducted risk assessments for dioxin-like compounds and have established exposure guidance values in terms of daily, weekly, or monthly intake of these compounds. The United States Agency for Toxic Substances and Disease Registry (ATSDR) has established a daily minimal risk level (MRL) of 1 pg/kg/day (ATSDR, 1999). The MRL is derived based on data from studies in rhesus monkeys administered 2,3,7,8-TCDD in diet. The WHO and Food and Agriculture Organization Joint Expert Committee on Food Additives (JECFA, 2001) established a provisional tolerable monthly intake of 70 pg/kg per m (equivalent to 2.3 pg/kg/day). The European Commission (ECSCF, 2001 ) and the United Kingdom (UKCOT, 2001) each established a tolerable intake rate equivalent to 2 pg/kg/day. In their more recent evaluations, these latter three organizations relied on data from rodent studies of 2,3,7,8-TCDD, rather than on the data from the monkey studies. They noted that data had recently been published regarding the monkey studies relied upon by ATSDR that indicated elevated PCB concentrations in the tissues of the 2,3,7,8-TCDD-exposed monkeys compared to the controls (Rier et al., 2001 ). These organizations concluded that the data suggested that the potential for inadvertent differential exposure of these monkeys to PCBs could have confounded the quantitative assessment of 2,3,7,8-TCDD exposure and response.
Biomonitoring equivalents have been estimated corresponding to each of these exposure guidance values . Each BE value is derived through consideration of the toxicological data underlying the respective exposure guidance value, understanding of the pharmacokinetics of dioxins in humans, and application of appropriate uncertainty factor components to the toxicological point of departure . The BE values can be used as screening tools to identify whether the measured population concentrations are in the region of low, medium, or high priority for risk assessment follow-up LaKind et al., 2008) . The BE values for PCDDs/F/s/ PCBs based on the available exposure guidance values are summarized in Table 1 . Table 2 gives serum PCDD/F TEQs for the mean and selected percentiles for the three time periods 1999-2000, 2001-2002, and 2003-2004 Table 3 shows serum PCDD/F TEQs by age group for the three sampling periods (weighted median values, nondetects assigned a value of either LOD/sq rt 2 or zero). Within each sampling period, PCDD/F serum levels generally increase with increasing age group regardless of the method used for assigning values below the detection limit. Focusing on the median values based on the use of LOD/sq rt 2, from the 1999-2000 to the 2003-2004 sampling period, PCDD/F serum levels decreased by 56% for the 12-to 19-year-old group, and by 38% for the 20-to 39-year olds. A slight nonsignificant decrease was observed for 40-to 59-year olds and a slight significant increase was found for 60 þ year olds.
Results

Temporal Changes in Serum PCDD/F Concentrations from 1999 to 2004
Temporal Changes in US Serum PCDD/F Serum Levels by Age
Impact of Measurements below the LOD
The large number of measures below the detection limit for all of the sampling periods impacts the overall population TEQ estimates, and the impact can be quite large. A common method for assigning a value for a measure below the detection limit is to use the LOD divided by the square root of 2, as is done in CDC's National Exposure Reports on the NHANES data (CDC, 2003 (CDC, , 2005 . Because the total TEQ is the sum of the concentrations of the 17 PCDDs/Fs (modified by their respective TEFs), inclusion of the value of LOD/sq rt 2 can contribute substantially to the overall TEQ.
With each sampling period, the number of nondetects contributing to the overall TEQ has decreased due to improved analytical methods and increased serum volumes (for the 2001-2002 and 2003-2004 Examining those PCDD/F congeners (using unweighted data), the general pattern in percent nondetects for the population is one of decreasing percent of nondetects with each successive sampling period, with the exception of CI, confidence interval; LOD, limit of detection; NA, not applicable; PCDD, polychlorinated dibenzodioxin; PCDF, polychlorinated dibenzofuran; TEQ, toxic equivalency. Measures below the detection limit were assigned a value of either LOD/sq rt 2 or zero to evaluate whether the temporal trends were strongly influenced by those measures.
Perspective on NHANES serum dioxin levels LaKind et al. (Table 4) .
We compared median weighted PCDD/F TEQs determined by setting nondetects equal to zero with those using LOD/sq rt 2 across the three sampling periods for individuals ages 20-60 þ years (Table 5) . With the LOD/sq rt 2 method, levels from 1999-2000 to [2001] [2002] were not significantly different; levels declined in [2003] [2004] . With nondetects assigned a value of zero, levels first increased significantly and then plateaued. As expected, serum TEQs were statistically significantly lower when nondetects were set to zero, especially for the 1999-2000 time period when percent nondetects were highest.
Comparison of Serum PCDD/F/PCB Levels to BEs
To provide public health perspective on the serum PCDD/F levels from the NHANES study, the most current data (the 2003-2004 sampling period) were compared to the BEs developed for PCDDs/Fs. However, as the exposure guidance values for dioxins encompass dioxins, furans, and several non-ortho-and mono-ortho-substituted PCBs, these compounds need to be included in the overall estimates of population means. The overall mean TEQ for serum PCDD/F/PCBs for the 2003-2004 sampling period is 15.9 pg TEQ/g lipid (95% CIs ¼ 15.3, 16.5), with the PCDD/Fs comprising approximately 82.5% of the total and the non-ortho-substituted PCBs equaling about 17% (the mono-ortho-substituted PCBs contribute less than 0.01%). Figure 1 shows the range of BE values in terms of serum lipid-adjusted concentrations of PCDDs/Fs/PCBs that are consistent with the exposure guidance values that have been established by various agencies (Table 1) . NHANES mean serum TEQ value is compared to the various BEs in Figure 1 . The mean serum TEQ is approximately equal to the BE based on ATSDR's MRL and approximately 2-4 times lower than the BEs based on the JECFA, European Commission, and UKCOT exposure guidance values. The mean, median, and 95th percentiles serum TEQs by age group are compared to the BE values in Table 6 .
Discussion
The NHANES serum PCDD/F data from 1999-2000 to 2003-2004 provide evidence that levels of these compounds These data further confirm that within each sampling period serum PCDD/F levels increase with increasing age (Bates et al., 2004; Patterson et al., 2004; Ferriby et al., 2007; Harden et al., 2007; Wong et al., 2008) , likely due to both the increased exposure duration in the older part of the population and to the exposure to past higher levels in the environment as compared to the exposures encountered by younger individuals today. The trend may also reflect a tendency toward slower elimination of these compounds in older versus younger individuals (Kreuzer et al., 1997; Aylward et al., 2005) .
Interpretation of the data across time is complicated by certain aspects of the data unique to the various sampling time periods; thus, caution should be exercised when evaluating trend information. First, the results from the 1999 to 2000 sampling period did not include two of the PCDD/F congeners (1, 2, 3, 4, 7, 2, 3, 4, 7, 8, . Although these congeners do not generally contribute substantially to the overall TEQ (e.g., for the 2003-2004 timeframe for ages 20 and over, the percent contribution of the two congeners to the total TEQ was 3.2%), the absence of these data would yield an underestimate of overall TEQ for that sampling period. Second, data for individuals ages 12-19 years were not available for the 2001-2002 sampling period, so temporal trends could not be assessed for that group. Further, due to the missing data on the youngest age group for [2001] [2002] , overall population percentiles shown in Table 2 exclude these younger individuals, which could possibly mask an overall population temporal decline, as this is the age group with the largest overall temporal decline in serum TEQs. Finally, changes in serum volumes, analytical methods, and detection limits from the 1999-2000 to the 2003-2004 sampling periods hinder our ability to compare data across time.
The percentage of the data below the detection limit generally decreased with each successive sampling period, and therefore the influence of value assigned (e.g., zero, LOD/sq rt 2) would likely have less of an impact on the overall TEQ estimates with each successive sampling period. However, a detailed understanding of the influence of data below the detection limit is made more difficult by the fact that 'The relative concentrations in humans of the 17 dioxin and furan congeners are determined by a combination of exposure (i.e., contact with congeners) and pharmacokinetic factors (i.e., absorption, distribution, metabolism, and excretion', Needham et al., 2007) . Thus, for each individual, there will be a unique influence of values below the LOD on his or her serum TEQ.
The population mean serum PCCD/F/PCB TEQ is close to the BE based on ATSDR's MRL and is approximately 2-4 times lower than the remaining BEs, placing the mean at the border between medium and low priority levels. Certain segments of the population have levels at the medium/high priority level (e.g., the 95th percentiles for ages 60 years and older). However, it is interesting to note that the BE values and underlying exposure guidance values are based on avoidance of developmental effects in offspring, the most sensitive toxicity end points identified to date. The mean TEQs for those people ages 12-39 (either at or approaching reproductive age) are lower than the BEs. The 95th percentiles for that age range are close to the ATSDR-based BE and below the JECFA-, European Commission-, and UKCOT-based BEs. Perspective on NHANES serum dioxin levels LaKind et al.
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